Biopharma capacity hike for Avid

- Last updated on GMT

Related tags: Biotechnology, Cell culture, Dna

Avid Bioservices is taking orders for a new 1,000-litre working
volume mammalian cell culture bioreactor that should be up and
running in July 2004.

The company, a subsidiary of Peregrine Pharmaceuticals, said that the expansion in bioreacter capacity has come about after a number of new manufacturing contracts. For example, at the end of November, the company disclosed a new agreement with an unnamed company to supply clinical supplies of a non-antibody protein.

"This bioreactor will substantially increase our capabilities for the current Good Manufacturing Practice (cGMP) manufacturing of monoclonal antibodies and other recombinant proteins,"​ said Jay Treat, Avid's vice president of business development.

Avid​ said that the reactor will be used in a number of manufacturing modes using its existing water-for-injection and clean steam systems. The company is currently taking orders for productions runs at the 1,000L scale for production slots in August 2004 and later.

Related topics: Markets & Regulations

Follow us

Products

View more

Webinars